As the Dow Jones Industrial Average experiences a prolonged losing streak and investors closely watch Federal Reserve decisions, market participants are seeking opportunities that might weather such volatility. Penny stocks, though often seen as speculative, can still hold potential when they exhibit strong financial fundamentals. These smaller or newer companies may offer unique value propositions and growth prospects that could appeal to investors looking for under-the-radar opportunities in today’s shifting economic landscape.
Name |
Share Price |
Market Cap |
Financial Health Rating |
Inter & Co (NasdaqGS:INTR) |
$4.42 |
$2.03B |
★★★★☆☆ |
QuantaSing Group (NasdaqGM:QSG) |
$3.08 |
$128.29M |
★★★★★★ |
BAB (OTCPK:BABB) |
$0.874625 |
$6.32M |
★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) |
$2.87 |
$89.78M |
★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) |
$0.23 |
$8.25M |
★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) |
$1.50 |
$48.84M |
★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) |
$4.50 |
$67.38M |
★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) |
$0.875 |
$13.39M |
★★★★★☆ |
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) |
$1.30 |
$65.6M |
★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) |
$0.8366 |
$75.59M |
★★★★★☆ |
Click here to see the full list of 716 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases, with a market cap of $6.71 million.
Operations: Edesa Biotech, Inc. currently does not report any revenue segments.
Market Cap: $6.71M
Edesa Biotech, a pre-revenue company with a market cap of US$6.71 million, faces significant challenges as highlighted by its auditor’s going concern doubts. Despite having no debt and an experienced management team, the company is unprofitable with increasing losses over the past five years and forecasts indicating further earnings decline. Recent capital raises through private placements and equity offerings have temporarily extended its cash runway but shareholder dilution remains a concern. The stock’s high volatility underscores investor uncertainty, compounded by an inability to achieve profitability within the next three years according to consensus estimates.